Integra LifeSciences Holdings Corp Stock News

NGVT, IART and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2023.

Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.

Integra announced a global recall of products made at its Boston facility. The company is also temporarily halting production at the facility.

Integra Lifesciences Holdings Corp (NASDAQ:IART) shares fell hard after it disclosed that after consultations with the US Food and Drug Administration (FDA) it has initiated a “voluntary global reca

Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.

In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.

Integra LifeSciences (IART) came out with quarterly earnings of $0.74 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.74 per share a year ago.

PRINCETON, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release first quarter 2023 financial r

Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.

Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q4 2022 Earnings Conference Call February 22, 2023 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witt

Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRINCETON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release fourth quarter 2022 financial r

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.